Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2024

20-10-2023 | Correction

Correction to: Pancreatic T cell protein–tyrosine phosphatase deficiency affects beta cell function in mice

Authors: Yannan Xi, Siming Liu, Ahmed Bettaieb, Kosuke Matsuo, Izumi Matsuo, Ellen Hosein, Samah Chahed, Florian Wiede, Sheng Zhang, Zhong-Yin Zhang, Rohit N. Kulkarni, Tony Tiganis, Fawaz G. Haj

Published in: Diabetologia | Issue 1/2024

Login to get access

Excerpt

Correction to: Diabetologia …
Metadata
Title
Correction to: Pancreatic T cell protein–tyrosine phosphatase deficiency affects beta cell function in mice
Authors
Yannan Xi
Siming Liu
Ahmed Bettaieb
Kosuke Matsuo
Izumi Matsuo
Ellen Hosein
Samah Chahed
Florian Wiede
Sheng Zhang
Zhong-Yin Zhang
Rohit N. Kulkarni
Tony Tiganis
Fawaz G. Haj
Publication date
20-10-2023
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2024
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-023-06023-1

Other articles of this Issue 1/2024

Diabetologia 1/2024 Go to the issue

Correction

Correction to: Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation

Letter

Using race as a social construct when looking at differences in racial associations between non‑alcoholic fatty liver disease and type 2 diabetes. Reply to Rollin FG, Washington C, Fluker S-A [letter]

Extended Article

ADGRL1 is a glucose receptor involved in mediating energy and glucose homeostasis

Article

The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT)

Article

Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study

Review

Novel type 2 diabetes therapies for management of CKD in patients with type 1 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits